Avenir Corp ownership in CTSO / Cytosorbents Corporation

세포흡착제 주식회사

US ˙ NasdaqCM ˙ US23283X2062

Security	CTSO / Cytosorbents Corporation
Institution	Avenir Corp
Latest Disclosed Ownership	5,230,099 shares
Ownership	8.30%

2026-02-13 - Avenir Corp has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,230,099 shares of Cytosorbents Corporation (US:CTSO). This represents 8.3 percent ownership of the company. In their previous filing dated 2025-02-14 , Avenir Corp had reported owning 3,093,946 shares, indicating an increase of 69.04 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-02-13	2026-02-13	13G/A	3,093,946	5,230,099	69.04	8.30	45.61
2025-02-14	2025-02-14	13G/A	3,051,402	3,093,946	1.39	5.70	-17.03
2024-02-14	2024-02-14	13G	2,447,089	3,051,402	24.70	6.87	22.46
2023-02-14	2023-02-14	13G/A	2,187,782	2,447,089	11.85	5.61	11.75
2022-08-11	2022-08-11	13G	2,156,833	2,187,782	1.43	5.02	1.41
2022-06-28	2022-06-28	13G/A	2,177,146	2,156,833	-0.93	4.95	-1.00
2022-04-25	2022-04-25	13G	2,088,071	2,177,146	4.27	5.00	4.17
2022-01-07	2022-01-07	13G/A	2,244,335	2,088,071	-6.96	4.80	-6.98
2021-12-13	2021-12-13	13G		2,244,335		5.16

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-14	2026-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	5,215,776	-14,323	-0.27	2,954	-11.67	0.3600
2026-02-13	2025-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	5,230,099	147,261	2.90	3,343	-29.58	0.3627
2025-11-14	2025-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	5,082,838	24,301	0.48	4,748	-26.68	0.4945
2025-08-14	2025-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	5,058,537	13,619	0.27	6,475	28.35	0.6655
2025-05-14	2025-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	5,044,918	1,950,972	63.06	5,045	79.18	0.5294
2025-02-13	2024-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	3,093,946	118,387	3.98	2,815	-36.93	0.2882
2024-11-14	2024-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,975,559	5,297	0.18	4,463	113.75	0.4501
2024-08-14	2024-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,970,262	-202,434	-6.38	2,088	-30.72	0.2028
2024-05-16	2024-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	3,172,696	121,294	3.98	3,014	-11.01	0.2580
2024-02-14	2023-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	3,051,402	334,005	12.29	3,387	-33.69	0.2929
2023-11-14	2023-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,717,397	-2,335	-0.09	5,109	-47.68	0.4782
2023-08-11	2023-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,719,732	164,179	6.42	9,764	13.37	0.8571
2023-05-15	2023-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,555,553	108,464	4.43	8,612	127.11	0.8146
2023-02-14	2022-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,447,089	132,235	5.71	3,793	20.46	0.3802
2022-11-15	2022-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,314,854	149,855	6.92	3,148	-33.60	0.3338
2022-08-11	2022-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	2,164,999	-11,510	-0.53	4,741	-31.72	0.4531
2022-05-16	2022-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	2,176,509	389,234	21.78	6,943	-7.29	0.5548
2022-02-16	2021-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	1,787,275	391,890	28.08	7,489	-33.91	0.5770
2021-11-12	2021-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	1,395,385	28,836	2.11	11,331	9.83	0.9524
2021-08-13	2021-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	1,366,549	1,007,679	280.79	10,317	231.20	0.8196
2021-05-14	2021-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	358,870	152,130	73.59	3,115	89.02	0.2693
2021-02-12	2020-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	206,740	16,500	8.67	1,648	8.64	0.1573
2020-11-13	2020-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	190,240	22,520	13.43	1,517	-8.61	0.1583
2020-08-14	2020-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	167,720	17,120	11.37	1,660	42.61	0.1891
2020-05-14	2020-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	150,600	0	0.00	1,164	100.69	0.1577
2020-02-14	2019-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	150,600	0	0.00	580	-23.48	0.0590
2019-11-13	2019-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	150,600	5,300	3.65	758	-21.04	0.0794
2019-08-12	2019-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	145,300	58,060	66.55	960	45.45	0.1001
2019-05-14	2019-03-31	13F	CYTOSORBENTS	COM NEW	23283X206	87,240	10,850	14.20	660	6.97	0.0700
2019-02-13	2018-12-31	13F	CYTOSORBENTS	COM NEW	23283X206	76,390	34,135	80.78	617	13.21	0.0770
2018-11-14	2018-09-30	13F	CYTOSORBENTS	COM NEW	23283X206	42,255	11,185	36.00	545	53.95	0.0599
2018-08-14	2018-06-30	13F	CYTOSORBENTS	COM NEW	23283X206	31,070	31,070		354		0.0404

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.